Premium
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?
Author(s) -
SPYROPOULOS A. C.,
GOLDENBERG N. A.,
KESSLER C. M.,
KITTELSON J.,
SCHULMAN S.,
TURPIE A. G. G.,
CUTLER N. R.,
HIATT W. R.,
HALPERIN J. L.
Publication year - 2012
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.12005
Subject(s) - rivaroxaban , medicine , dabigatran , antithrombotic , clinical trial , dosing , warfarin , direct thrombin inhibitor , apixaban , vitamin k antagonist , intensive care medicine , ximelagatran , pharmacology , atrial fibrillation
Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AGG, Cutler NR, Hiatt WR, Halperin JL. Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? J Thromb Haemost 2012; 10: 2621–4.